Published in Lancet Neurol on April 01, 2006
Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) | NCT02308137
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol (2009) 2.56
Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci (2008) 1.24
Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol (2009) 1.01
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis. PLoS One (2015) 1.00
Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clin Proteomics (2012) 0.98
Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord (2010) 0.98
Grey matter damage in multiple sclerosis: a pathology perspective. Prion (2013) 0.93
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol Commun (2014) 0.92
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J Neurol (2012) 0.89
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis. J Neuroimmunol (2012) 0.88
Axonal damage in multiple sclerosis. Mt Sinai J Med (2011) 0.87
The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. PLoS One (2011) 0.86
Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease. PLoS One (2013) 0.86
Protective and detrimental roles for regulatory T cells in a viral model for multiple sclerosis. Brain Pathol (2014) 0.85
Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease? Pathophysiology (2012) 0.85
Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis. Ther Adv Neurol Disord (2008) 0.82
Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J Neural Transm (Vienna) (2007) 0.81
Microwave and magnetic (M(2) ) proteomics of the experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Electrophoresis (2012) 0.81
Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One (2012) 0.81
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis. J Neuroinflammation (2010) 0.81
Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2008) 0.80
Microwave & magnetic (M2) proteomics reveals CNS-specific protein expression waves that precede clinical symptoms of experimental autoimmune encephalomyelitis. Sci Rep (2014) 0.80
Isolated, relapsing and progressive demyelinating diseases of the central nervous system. J Neurol (2008) 0.80
Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. PLoS One (2013) 0.79
Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun (2013) 0.79
The role of infections in the pathogenesis and course of multiple sclerosis. Ann Indian Acad Neurol (2010) 0.79
Determinants of disability in multiple sclerosis: an immunological and MRI study. Biomed Res Int (2014) 0.78
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences. Int J MS Care (2016) 0.78
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology (2016) 0.78
Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools. Toxins (Basel) (2015) 0.78
Treatment trials in progressive MS--current challenges and future directions. Nat Rev Neurol (2013) 0.77
Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1. PLoS One (2015) 0.77
New and emerging immune-targeted drugs for the treatment of multiple sclerosis. Br J Clin Pharmacol (2014) 0.77
Drug therapy for multiple sclerosis. CMAJ (2014) 0.76
Beta-interferon exposure and onset of secondary progressive multiple sclerosis. Eur J Neurol (2015) 0.76
Multiple sclerosis and the blood-central nervous system barrier. Cardiovasc Psychiatry Neurol (2013) 0.76
Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clin Exp Immunol (2015) 0.76
An integrated approach to design novel therapeutic interventions for demyelinating disorders. Eur J Neurosci (2012) 0.75
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis. BMC Neurol (2015) 0.75
Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial. Pilot Feasibility Stud (2017) 0.75
Distinguishing Susac's syndrome from multiple sclerosis. J Neurol (2014) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 5.31
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med (2010) 4.08
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature (2005) 3.53
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol (2012) 2.68
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology (2014) 2.41
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol (2009) 2.20
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2012) 2.13
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2012) 2.05
Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol (2005) 2.01
Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology (2012) 2.00
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain (2009) 1.89
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet (2010) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol (2008) 1.85
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J (2009) 1.78
A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol (2010) 1.77
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler (2012) 1.75
Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol (2009) 1.73
White matter damage in primary progressive aphasias: a diffusion tensor tractography study. Brain (2011) 1.73
Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage (2010) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Resting state fMRI in Alzheimer's disease: beyond the default mode network. Neurobiol Aging (2011) 1.70
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain (2004) 1.70
Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol (2002) 1.68
Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain (2008) 1.67
MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett (2011) 1.64
Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke (2008) 1.63
Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke (2006) 1.63
Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.59
Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. Biol Psychiatry (2013) 1.58
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol (2010) 1.55
Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol (2010) 1.53
MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Mov Disord (2010) 1.52
Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol (2011) 1.51
Language networks in semantic dementia. Brain (2009) 1.50
Weighing brain activity with the balance: Angelo Mosso's original manuscripts come to light. Brain (2013) 1.50
Brain network connectivity assessed using graph theory in frontotemporal dementia. Neurology (2013) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A (2009) 1.49
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr (2004) 1.48